相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab
Brigida Barberio et al.
INFLAMMATORY BOWEL DISEASES (2020)
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Javier P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2020)
Serum Biomarkers for Inflammatory Bowel Disease
Peng Chen et al.
FRONTIERS IN MEDICINE (2020)
Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
Renaud Gaujoux et al.
GUT (2019)
What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?
Christopher Ma et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Fbxw7 increases CCL2/7 in CX3CR1hi macrophages to promote intestinal inflammation
Jia He et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Circulating Picomolar Levels of CCL2 Downregulate Ongoing Chronic Experimental Autoimmune Encephalomyelitis by Induction of Regulatory Mechanisms
Nathali Kaushansky et al.
JOURNAL OF IMMUNOLOGY (2019)
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
Youlian Zhou et al.
MSYSTEMS (2018)
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy
H. Bar-Yoseph et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?
Lorant Gonczi et al.
JOURNAL OF CROHNS & COLITIS (2017)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
N. S. Ding et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease
Grant E. Barber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
Mahmoud H. Mosli et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease
Paolo Biancheri et al.
GASTROENTEROLOGY (2015)
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse
Konstantinos Papamichael et al.
INFLAMMATORY BOWEL DISEASES (2015)
Response to Infliximab Therapy in Ulcerative Colitis is Associated With Decreased Monocyte Activation, Reduced CCL2 Expression and Downregulation of Tenascin C
Maria K. Magnusson et al.
JOURNAL OF CROHNS & COLITIS (2015)
Matrix Metalloproteases Role in Bowel Inflammation and Inflammatory Bowel Disease: An Up to Date Review
Nuala R. O'Shea et al.
INFLAMMATORY BOWEL DISEASES (2014)
P495 High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
E. Rodrigues-Pinto et al.
Journal of Crohns & Colitis (2013)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease
George P. Christophi et al.
INFLAMMATORY BOWEL DISEASES (2012)
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2012)
Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab
Kotaro Ogawa et al.
JOURNAL OF CROHNS & COLITIS (2012)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Anti-TNF therapy: Safety aspects of taking the risk
Hemda Rosenblum et al.
AUTOIMMUNITY REVIEWS (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Monocyte chemoattractant protein-1: A key mediator in inflammatory processes
Esther Melgarejo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease - Elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin
O Grip et al.
INFLAMMATORY BOWEL DISEASES (2004)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Prediction of response to treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease.
T Andus et al.
GASTROENTEROLOGY (2001)
Improvement of arthritis arthralgia after treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease.
T Andus et al.
GASTROENTEROLOGY (2001)
分享论文
